Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Trinity Biotech (TRIB) EBITDA Margin (2016 - 2024)

Trinity Biotech's EBITDA Margin history spans 16 years, with the latest figure at 72.61% for Q4 2024.

  • On a quarterly basis, EBITDA Margin fell 4446.0% to 72.61% in Q4 2024 year-over-year; TTM through Dec 2024 was 34.38%, a 1321.0% increase, with the full-year FY2025 number at 36.06%, down 168.0% from a year prior.
  • EBITDA Margin hit 72.61% in Q4 2024 for Trinity Biotech, down from 16.88% in the prior quarter.
  • Over the last five years, EBITDA Margin for TRIB hit a ceiling of 28.38% in Q3 2020 and a floor of 106.86% in Q2 2023.
  • Historically, EBITDA Margin has averaged 17.79% across 5 years, with a median of 14.44% in 2022.
  • Biggest five-year swings in EBITDA Margin: tumbled -9486bps in 2023 and later skyrocketed 8129bps in 2024.
  • Tracing TRIB's EBITDA Margin over 5 years: stood at 27.67% in 2020, then plummeted by -90bps to 2.88% in 2021, then plummeted by -1899bps to 51.87% in 2022, then surged by 46bps to 28.14% in 2023, then plummeted by -158bps to 72.61% in 2024.
  • Business Quant data shows EBITDA Margin for TRIB at 72.61% in Q4 2024, 16.88% in Q3 2024, and 25.58% in Q2 2024.